Analysts Expect Emergent Biosolutions Inc (EBS) Will Announce Quarterly Sales of $182.16 Million

Wall Street analysts expect Emergent Biosolutions Inc (NYSE:EBS) to report $182.16 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Emergent Biosolutions’ earnings. The highest sales estimate is $184.60 million and the lowest is $179.71 million. Emergent Biosolutions reported sales of $151.66 million in the same quarter last year, which suggests a positive year over year growth rate of 20.1%. The firm is scheduled to report its next earnings report on Thursday, February 22nd.

According to Zacks, analysts expect that Emergent Biosolutions will report full-year sales of $182.16 million for the current fiscal year. For the next financial year, analysts anticipate that the business will report sales of $715.70 million per share. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Emergent Biosolutions.

Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.41 by $0.32. Emergent Biosolutions had a net margin of 15.60% and a return on equity of 15.20%. The company had revenue of $149.43 million during the quarter, compared to analysts’ expectations of $124.55 million. During the same period last year, the company posted $0.56 earnings per share. The business’s revenue for the quarter was up 4.6% on a year-over-year basis.

Several brokerages have commented on EBS. Goldman Sachs Group began coverage on shares of Emergent Biosolutions in a report on Wednesday, January 24th. They issued a “neutral” rating and a $55.00 target price for the company. Chardan Capital raised their target price on shares of Emergent Biosolutions from $47.00 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, January 16th. Finally, Zacks Investment Research cut shares of Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 11th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Emergent Biosolutions presently has a consensus rating of “Buy” and an average target price of $51.00.

Emergent Biosolutions (NYSE:EBS) opened at $45.64 on Tuesday. Emergent Biosolutions has a fifty-two week low of $27.94 and a fifty-two week high of $51.25. The company has a market cap of $2,361.58, a PE ratio of 25.29, a price-to-earnings-growth ratio of 0.98 and a beta of 1.28. The company has a quick ratio of 6.46, a current ratio of 7.37 and a debt-to-equity ratio of 0.38.

In related news, Chairman Fuad El-Hibri sold 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $40.37, for a total transaction of $1,614,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Zsolt Harsanyi sold 7,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $42.47, for a total transaction of $297,290.00. Following the sale, the director now owns 37,077 shares of the company’s stock, valued at $1,574,660.19. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 165,722 shares of company stock valued at $7,219,341. 16.50% of the stock is currently owned by corporate insiders.

Several hedge funds have recently bought and sold shares of EBS. Ameritas Investment Partners Inc. lifted its stake in Emergent Biosolutions by 23.2% in the second quarter. Ameritas Investment Partners Inc. now owns 3,118 shares of the biopharmaceutical company’s stock valued at $106,000 after acquiring an additional 587 shares during the last quarter. First Quadrant L P CA acquired a new stake in Emergent Biosolutions in the third quarter valued at approximately $157,000. Meeder Asset Management Inc. lifted its stake in Emergent Biosolutions by 94.7% in the third quarter. Meeder Asset Management Inc. now owns 4,732 shares of the biopharmaceutical company’s stock valued at $191,000 after acquiring an additional 2,302 shares during the last quarter. Victory Capital Management Inc. acquired a new stake in Emergent Biosolutions in the third quarter valued at approximately $191,000. Finally, GW&K Investment Management LLC acquired a new stake in Emergent Biosolutions in the fourth quarter valued at approximately $200,000. Institutional investors and hedge funds own 74.31% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/06/analysts-expect-emergent-biosolutions-inc-ebs-will-announce-quarterly-sales-of-182-16-million.html.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Get a free copy of the Zacks research report on Emergent Biosolutions (EBS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply